Another flaw in this study is that it apparently assigns the same value to each of the "negative predictors." That is to say 1 point for gender, 1 point for cirrhosis, etc., etc. There is no way that gender and cirrhosis are of equal value in determining treatment outcomes for this combo (or probably any other combo).
If I was going to rely on statistics to predict outcome, I would be more likely to rely on the clinical trial data, and even those are flawed and have limited predictability value.
Tig said
May 18, 2014
Would a "caveat emptor" apply here? There is indeed an assumption of average weight in the female gender Isis, it's called, "You look great honey, I wouldn't change a thing..." >>>>>BIG GRIN<<<<<
Tig
Isiscat2011 said
May 18, 2014
P.S. I should qualify that statement: the average weight for an AMERICAN male is 180 (height 5'9").
No need to post the average weight of women; we won't EVEN be going there, girlfriend.
Isiscat2011 said
May 18, 2014
I'm not sure how promising I would interpret this, particularly if I was a male (most men do weigh at least 165 pounds, most do not have the CC allele, and most have VLs > 800K) but don't be discouraged if you have more than 3 of the listed predictors.
First and foremost, these study results are only meaningful if you are on the Interferon/Riba/Sovaldi combo.
Additionally, this study (or at least what is written in the article about this study) considers only efficacy (SVR rates) and an equally important factor in the equation is safety. Using safer drugs will allow relapsers to more safely retreat with much greater ease if necessary. Many docs recommend that people on Int/Riba combos don't even try to re-treat for at least 12-18 months after a failed older tx; with safer drugs re-treatment can probably begin much sooner.
Additionally, if you view the study critically you will see it contains many flaws, including but not limited to, the following:
1) It is a relatively small sample and, therefore, not necessarily representative of the results that may be seen in the general public,
2) It fails to distinguish results among the specific genotypes.
longld said
May 18, 2014
Tig, copied the negative predictors summary - very promising!
Six negative predictors were associated with relapse among all patients:
baseline hepatitis C virus (HCV) RNA 800,000 IU/mL and
previous treatment failure.
Ninety percent or more in patients in all genotypes still achieved SVR when they had three or fewer negative predictors. SVR rates declined among patients with five or more negative predictors.
-- Edited by longld on Sunday 18th of May 2014 05:54:10 AM
Tig said
May 18, 2014
I get email updates containing random new, sometimes dated, yet occasionally interesting articles. Take a look and see what you think, who knows, you might find the answer to that question that kept you awake all night, or maybe not, but it's all food for thought!
Hahaha.........
Another flaw in this study is that it apparently assigns the same value to each of the "negative predictors." That is to say 1 point for gender, 1 point for cirrhosis, etc., etc. There is no way that gender and cirrhosis are of equal value in determining treatment outcomes for this combo (or probably any other combo).
If I was going to rely on statistics to predict outcome, I would be more likely to rely on the clinical trial data, and even those are flawed and have limited predictability value.
Would a "caveat emptor" apply here? There is indeed an assumption of average weight in the female gender Isis, it's called, "You look great honey, I wouldn't change a thing..." >>>>>BIG GRIN<<<<<
Tig
P.S. I should qualify that statement: the average weight for an AMERICAN male is 180 (height 5'9").
No need to post the average weight of women; we won't EVEN be going there, girlfriend.
I'm not sure how promising I would interpret this, particularly if I was a male (most men do weigh at least 165 pounds, most do not have the CC allele, and most have VLs > 800K) but don't be discouraged if you have more than 3 of the listed predictors.
First and foremost, these study results are only meaningful if you are on the Interferon/Riba/Sovaldi combo.
Additionally, this study (or at least what is written in the article about this study) considers only efficacy (SVR rates) and an equally important factor in the equation is safety. Using safer drugs will allow relapsers to more safely retreat with much greater ease if necessary. Many docs recommend that people on Int/Riba combos don't even try to re-treat for at least 12-18 months after a failed older tx; with safer drugs re-treatment can probably begin much sooner.
Additionally, if you view the study critically you will see it contains many flaws, including but not limited to, the following:
1) It is a relatively small sample and, therefore, not necessarily representative of the results that may be seen in the general public,
2) It fails to distinguish results among the specific genotypes.
Tig, copied the negative predictors summary - very promising!
Six negative predictors were associated with relapse among all patients:
male sex,
weighing at least 75 kg,
IL-28B non-cc genotype,
cirrhosis,
baseline hepatitis C virus (HCV) RNA 800,000 IU/mL and
previous treatment failure.
Ninety percent or more in patients in all genotypes still achieved SVR when they had three or fewer negative predictors. SVR rates declined among patients with five or more negative predictors.
-- Edited by longld on Sunday 18th of May 2014 05:54:10 AM
I get email updates containing random new, sometimes dated, yet occasionally interesting articles. Take a look and see what you think, who knows, you might find the answer to that question that kept you awake all night, or maybe not, but it's all food for thought!
Tig
PCP training program increased number of patients receiving HCV treatment
Tacrolimus triple therapy reduced fibrosis among cirrhotic HCV patients after liver transplantation
Simeprevir (Olysio): A New NS3/4A Protease Inhibitor
HCV patients treated with sofosbuvir maintained high SVR despite negative predictors
Researchers Identify HCV Surface Protein, Raise Hope for Vaccine